Article
Loss of Drp1 function alters OPA1 processing and changes mitochondrial membrane organization.
Silence Therapeutics AG, 13125 Berlin, Germany.
Experimental Cell Research (impact factor:
3.58).
06/2009;
315(13):2165-80.
DOI:10.1016/j.yexcr.2009.04.016
pp.2165-80
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models.
[show abstract] [hide abstract]
ABSTRACT: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hematogenous metastasis to the target organ lung in four different preclinical mouse models. Atu027 compared with vehicle or control small interfering RNA lipoplexes was tested in two experimental lung metastasis models (Lewis lung carcinoma, B16V) and spontaneous metastasis mouse models (MDA-MB-435, MDA-MB-231, mammary fat pad). Different dosing schedules (repeated low volume tail vein injections) were applied to obtain insight into effective Atu027 treatment. Primary tumor growth and lung metastasis were measured, and tissues were analyzed by immunohistochemistry and histology. In vitro studies in human umbilical vein endothelial cells were carried out to provide an insight into molecular changes on depletion of PKN3, in support of efficacy results. Intravenous administration of Atu027 prevents pulmonary metastasis. In particular, formation of spontaneous lung metastasis was significantly inhibited in animals with large tumor grafts as well as in mice with resected primary mammary fat pad tumors. In addition, we provide evidence that an increase in VE-cadherin protein levels as a downstream result of PKN3 target gene inhibition may change endothelial function, resulting in reduced colonization and micrometastasis formation. Atu027 can be considered as a potent drug for preventing lung metastasis formation, which might be suitable for preventing hematogenous metastasis in addition to standard cancer therapy.Clinical Cancer Research 11/2010; 16(22):5469-80. · 7.74 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
branched mitochondrial network
cell proliferation
cultured HeLa
Drp1 expression results
Drp1 function changes mitochondrial morphology
Drp1 results
HUVEC cells
Mfn1 action
Mfn1 levels
mitochondrial fission
mitochondrial fusion machinery
mitochondrial morphology
Mitofusin 1
modified proteolytic processing
OPA1 processing
particular proteolytic short-OPA1
protein levels
proteins Yme1L
s-OPA1 mitochondrial membrane
unopposed fusion